Advertisement

Mitochondrial Involvement in Drug-Induced Liver Injury

  • Dominique PessayreEmail author
  • Abdellah Mansouri
  • Alain Berson
  • Bernard Fromenty
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 196)

Abstract

Mitochondrial dysfunction is a major mechanism of liver injury. A parent drug or its reactive metabolite can trigger outer mitochondrial membrane permeabilization or rupture due to mitochondrial permeability transition. The latter can severely deplete ATP and cause liver cell necrosis, or it can instead lead to apoptosis by releasing cytochrome c, which activates caspases in the cytosol. Necrosis and apoptosis can trigger cytolytic hepatitis resulting in lethal fulminant hepatitis in some patients. Other drugs severely inhibit mitochondrial function and trigger extensive microvesicular steatosis, hypoglycaemia, coma, and death. Milder and more prolonged forms of drug-induced mitochondrial dysfunction can also cause macrovacuolar steatosis. Although this is a benign liver lesion in the short-term, it can progress to steatohepatitis and then to cirrhosis. Patient susceptibility to drug-induced mitochondrial dysfunction and liver injury can sometimes be explained by genetic or acquired variations in drug metabolism and/or elimination that increase the concentration of the toxic species (parent drug or metabolite). Susceptibility may also be increased by the presence of another condition, which also impairs mitochondrial function, such as an inborn mitochondrial cytopathy, β-oxidation defect, certain viral infections, pregnancy, or the obesity-associated metabolic syndrome. Liver injury due to mitochondrial dysfunction can have important consequences for pharmaceutical companies. It has led to the interruption of clinical trials, the recall of several drugs after marketing, or the introduction of severe black box warnings by drug agencies. Pharmaceutical companies should systematically investigate mitochondrial effects during lead selection or preclinical safety studies.

Keywords

Mitochondria Drug-induced liver injury Hepatotoxicity Steatosis Hepatitis 

References

  1. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG, Caldwell J, Day CP (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430–1440PubMedCrossRefGoogle Scholar
  2. Anandatheerthavarada H, Addya S, Dwivedi RS, Biswas G, Mullick J, Avadhani NG (1997) Localization of multiple forms of inducible cytochromes P450 in rat liver mitochondria: immunological characteristics and patterns of xenobiotic substrate metabolism. Arch Biochem Biophys 339:136–150PubMedCrossRefGoogle Scholar
  3. Anandatheerthavarada HK, Vijayasarathy C, Bhagwat SV, Biswas G, Mullick J, Avadhani NG (1999) Physiological role of the N-terminal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesis. J Biol Chem 274:6617–6625PubMedCrossRefGoogle Scholar
  4. Babany G, Larrey D, Pessayre D, Degott C, Rueff B, Benhamou JP (1987) Chronic active hepatitis caused by benzarone. J Hepatol 5:332–335PubMedCrossRefGoogle Scholar
  5. Bae MA, Song BY (2003) Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 63:401–408PubMedCrossRefGoogle Scholar
  6. Bajt ML, Knight TR, Farhood A, Jaeschke H (2003) Scavenging peroxynitrite with glutathione promotes regeneration and enhances survival during acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther 307:67–73PubMedCrossRefGoogle Scholar
  7. Banasch M, Goetze O, Knyhala K, Potthoff A, Schlottmann R, Kwiatek MA, Bulut K, Schmitz F, Schmidt WE, Brockmeyer NH (2006) Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 20:1554–1556PubMedCrossRefGoogle Scholar
  8. Barile M, Valenti D, Passarella S, Quagliariello E (1997) 3′-Azido-3′-deoxythymidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Biochem Pharmacol 53:913–920PubMedCrossRefGoogle Scholar
  9. Bartley PB, Westacott L, Boots RJ, Lawson M, Potter JM, Hyland VJ, Woods ML II (2001) Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy. AIDS 15:419–420PubMedCrossRefGoogle Scholar
  10. Beaune P, Pessayre D, Dansette P, Mansuy D, Manns M (1994) Autoantibodies against cytochromes P450: role in human diseases. Adv Pharmacol 30:199–245PubMedCrossRefGoogle Scholar
  11. Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Métivier D, Marchetti P, Brenner C, Kroemer G (2001) Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20:7579–7587PubMedCrossRefGoogle Scholar
  12. Bergeron RJ, Neims AH, McManis JS, Hawthorne TR, Vinson JR, Bortell R, Ingeno MJ (1988) Synthetic polyamine analogues as antineoplastics. J Med Chem 31:1183–1190PubMedCrossRefGoogle Scholar
  13. Berneburg M, Grether-Beck S, Kürten V, Ruzicka T, Briviba K, Sies H, Krutmann J (1999) Singlet oxygen mediates the UVA-induced generation of the photoaging-associated mitochondrial common deletion. J Biol Chem 274:15345–15349PubMedCrossRefGoogle Scholar
  14. Berson A, Renault S, Lettéron P, Robin MA, Fromenty B, Fau D, Le Bot MA, Riché C, Durand-Schneider AM, Feldmann G, Pessayre D (1996) Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 110:1878–1890PubMedCrossRefGoogle Scholar
  15. Berson A, De Beco V, Lettéron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, Pessayre D (1998) Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764–774PubMedCrossRefGoogle Scholar
  16. Berson A, Descatoire V, Sutton A, Fau D, Maulny B, Vadrot N, Feldmann G, Berthon B, Tordjmann T, Pessayre D (2001a) Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem in rat hepatocytes. Role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther 299:793–800PubMedGoogle Scholar
  17. Berson A, Fau D, Fornacciari R, Degove-Goddard P, Sutton A, Descatoire V, Haouzi D, Lettéron P, Moreau A, Feldmann G, Pessayre D (2001b) Mechanism for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 34:261–269PubMedCrossRefGoogle Scholar
  18. Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, Marcellin P, Degott C, Valla D, Pessayre D (2001c) Hepatitis after buprenorphine misuse in heroin addicts. J Hepatol 34:346–350PubMedCrossRefGoogle Scholar
  19. Berson A, Cazanave S, Descatoire V, Tinel M, Grodet A, Wolf C, Feldmann G, Pessayre D (2006) The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. J Pharmacol Exp Ther 318:444–454PubMedCrossRefGoogle Scholar
  20. Bioulac-Sage P, Parrot-Roulaud F, Mazat JP, Lamireau T, Coquet M, Sandler B, Demarquez JL, Cormier V, Munnich A, Carré M, Balabaud C (1993) Fatal neonatal liver failure and mitochondrial cytopathy (oxidative phosphorylation deficiency): a light and electron microscopic study of the liver. Hepatology 18:839–846PubMedCrossRefGoogle Scholar
  21. Bjorge SM, Baillie TA (1985) Inhibition of medium-chain fatty acid β-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem Biophys Res Commun 132:245–252PubMedCrossRefGoogle Scholar
  22. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH (2003) Cytochrome c binds to inositol (1, 4, 5) triphosphate receptors, amplifying calcium-dependent apoptosis. Nature Cell Biol 5:1051–1061PubMedCrossRefGoogle Scholar
  23. Borutaité V, Brown GC (1996) Rapid reduction of nitric oxide by mitochondria, and reversible inhibition of mitochondrial respiration by nitric oxide. Biochem J 315:295–299PubMedGoogle Scholar
  24. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, Ojcius DM, Jäättelä M, Kroemer G (2003a) Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med 197:1323–1334PubMedCrossRefGoogle Scholar
  25. Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HLA, Roumier T, Perfettini JL, Kroemer G (2003b) Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22:3927–3936PubMedCrossRefGoogle Scholar
  26. Bravo JF, Jacobson MP, Mertens BF (1997) Fatty liver and pleural effusion with ibuprofen therapy. Ann Intern Med 87:200–201Google Scholar
  27. Brivet FG, Nion I, Mégarbane B, Slama A, Brivet P, Rustin P, Munnich A (1999) Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction? J Hepatol 30:364–365Google Scholar
  28. Bröcker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FAE, Giaccone G (2004) Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 64:27–30CrossRefGoogle Scholar
  29. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U (2005) Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. Br Med J 330:932CrossRefGoogle Scholar
  30. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD Jr (1999) Mitochondrial abnormalities in nonalcoholic steatohepatitis. J Hepatol 31:430–434PubMedCrossRefGoogle Scholar
  31. Castéra L, Kalinsky E, Bedossa P, Tertian G, Buffet C (1999) Macrovacuolar steatosis induced by interferon alfa therapy for chronic myelogenous leukemia. Liver 19:259–260PubMedCrossRefGoogle Scholar
  32. Catisti R, Vercesi A (1999) The participation of pyridine nucleotides redox state and reactive oxygen in the fatty acid-induced permeability transition in rat liver mitochondria. FEBS Lett 464:97–101PubMedCrossRefGoogle Scholar
  33. Chabrol B, Mancini J, Chretien D, Rustin P, Munnich A, Pinsard N (1994) Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 153:133–135PubMedGoogle Scholar
  34. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombès A, Schaeffer A, Zafrani ES (2000) Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 32:364–365CrossRefGoogle Scholar
  35. Chen CH, Cheng YC (1989) Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 264:11934–11937PubMedGoogle Scholar
  36. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM (1999) Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study. JAMA 282:1659–1664PubMedCrossRefGoogle Scholar
  37. Cortopassi GA, Shibata D, Soong NW, Arnheim N (1992) A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc Natl Acad Sci USA 89: 7370–7374PubMedCrossRefGoogle Scholar
  38. Costantini P, Chernyak BV, Petronilli V, Bernardi P (1996) Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem 271:6746–6751PubMedCrossRefGoogle Scholar
  39. Cover C, Mansouri A, Knight TR, Bajt ML, Lemasters JJ, Pessayre D, Jaeschke H (2005) Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. J Pharmacol Exp Ther 315:879–887PubMedCrossRefGoogle Scholar
  40. Cross RL, Kohlbrenner WE (1978) Efrapeptin prevents modification by phenylglyoxal of an essential arginyl residue in mitochondrial adenosine triphosphatase. J Biol Chem 253:4865–4873PubMedGoogle Scholar
  41. Dai Y, Rashba-Step J, Cederbaum AI (1993) Stable expression of human cytochrome P450 2E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 32:6928–6937PubMedCrossRefGoogle Scholar
  42. Danan G, Descatoire V, Pessayre D (1981) Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 218:509–514PubMedGoogle Scholar
  43. Danan G, Trunet P, Bernuau J, Degott C, Babany G, Pessayre D, Rueff B, Benhamou JP (1985) Pirprofen-induced fulminant hepatitis. Gastroenterology 89:210–213PubMedGoogle Scholar
  44. de la Asuncion JG, del Olmo ML, Sastre J, Millan A, Pellin A, Pallardo FV (1998) AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 102:4–9PubMedCrossRefGoogle Scholar
  45. de la Asuncion JG, del Olmo ML, Sastre J, Pallardo FV, Vina J (1999) Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 29:985–987PubMedCrossRefGoogle Scholar
  46. de la Iglesia FA, Feuer G, Takada A, Matsuda Y (1974) Morphologic studies on secondary phospholipidosis in humans. Lab Invest 4:539–549Google Scholar
  47. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S, Boelaert JR (2006) Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42:1111–1117PubMedCrossRefGoogle Scholar
  48. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, NGuyen R, Tinel M, Lettéron P, Degott C, Feldmann G, Pessayre D, Fromenty B (2002) Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 123:1278–1290PubMedCrossRefGoogle Scholar
  49. Deniaud A, Sharaf el dein O, Maillier E, Poncet D, Kroemer G, Lemaire C, Brenner C (2008) Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27(3):285–299Google Scholar
  50. Derks TGJ, van Dijk TH, Grefhorst A, Rake JP, Smit GPA, Kuipers F, Reijngoud DJ (2008) Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 47:1032–1042PubMedCrossRefGoogle Scholar
  51. Deschamps D, Fisch C, Fromenty B, Berson A, Degott C, Pessayre D (1991) Inhibition by salicylic acid of the activation and thus oxidation of long-chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 259:894–904PubMedGoogle Scholar
  52. Deschamps D, De Beco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D (1994) Inhibition by perhexiline of oxidative phosphorylation and the ß-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 19:948–961PubMedCrossRefGoogle Scholar
  53. DiMauro S, Schon EA (1998) Nuclear power and mitochondrial disease. Nature Genet 19:214–215PubMedCrossRefGoogle Scholar
  54. Dutertre JP, Bastides F, Jonville AP, De Muret A, Sonneville A, Larrey D, Autret E (1991) Microvesicular steatosis after ketoprofen administration. Eur J Gastroenterol Hepatol 3:953–954Google Scholar
  55. Ebel RE, Lardy HA (1975) Influence of aurovertin on mitochondrial ATPase activity. J Biol Chem 250:4992–4995PubMedGoogle Scholar
  56. Ebert EC, Sun EA, Wright SH, Decker JP, Librizzi RJ, Bolognese RJ, Lipshutz WH (1984) Does early diagnosis and delivery in acute fatty liver of pregnancy lead to improvement in maternal and infant survival? Digest Dis Sci 29:453–455PubMedCrossRefGoogle Scholar
  57. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM (2004) In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24:6728–6741PubMedCrossRefGoogle Scholar
  58. Esnault C, Brown SC, Segal-Bendirdjian E, Coulaud D, Mishal Z, Roques BP, Le Pecq JB (1990) Selective alteration of mitochondrial function by dirtercalinium (NSC 335153), a DNA bisintercalating agent. Biochem Pharmacol 39:109–122PubMedCrossRefGoogle Scholar
  59. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC (1999) Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA 96:4820–4825Google Scholar
  60. Farrell G (1994) Drug-induced liver disease. Churchill-Livingstone, LondonGoogle Scholar
  61. Fau D, Lekehal M, Farrell G, Moreau A, Moulis C, Feldmann G, Haouzi D, Pessayre D (1997) Diterpenoids from germander, a herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 113:1334–1346PubMedCrossRefGoogle Scholar
  62. Feldmann G, Haouzi D, Moreau A, Durand-Scheider AM, Bringuier A, Berson A, Mansouri A, Fau D, Pessayre D (2000) Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology 31:674–683PubMedCrossRefGoogle Scholar
  63. Feldstein AE, Werneburg NW, Li ZZ, Bronk SF, Gores GJ (2006) Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 290:1339–1346CrossRefGoogle Scholar
  64. Fernandez-Checa JC, Garcia-Ruiz C, Ookhtens M, Kaplowitz N (1991) Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats. Tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress. J Clin Invest 87:397–405PubMedCrossRefGoogle Scholar
  65. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR (1999) Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 274:2225–2233Google Scholar
  66. Fisher R, Schmitt M, Bode JG, Häussinger D (2001) Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology 120:1212–1226CrossRefGoogle Scholar
  67. Forsyth BW, Horwitz RI, Acampora D, Shapiro ED, Viscoli CM, Feinstein AR, Henner R, Holabird NB, Jones BA, Karabelas ADE, Kramer MS, Miclette M, Wells JA (1989) New epidemiologic evidence confirming that bias does not explain the aspirin/Reye’s syndrome association. JAMA 261:2517–2524PubMedCrossRefGoogle Scholar
  68. Fréneaux E, Labbe G, Lettéron P, Le Dinh T, Degott C, Genève J, Larrey D, Pessayre D (1988) Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 8:1056–1062PubMedCrossRefGoogle Scholar
  69. Fréneaux E, Fromenty B, Berson A, Labbe G, Degott C, Lettéron P, Larrey D, Pessayre D (1990) Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids. J Pharmacol Exp Ther 255:529–535PubMedGoogle Scholar
  70. Fromenty B, Pessayre D (1995) Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67:101–154PubMedCrossRefGoogle Scholar
  71. Fromenty B, Fréneaux E, Labbe G, Deschamps D, Larrey D, Lettéron D, Pessayre D (1989) Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 38:3743–3751PubMedCrossRefGoogle Scholar
  72. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, Lettéron P, Pessayre D (1990a) Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 255:1371–1376PubMedGoogle Scholar
  73. Fromenty B, Fisch C, Berson A, Lettéron P, Larrey D, Pessayre D (1990b) Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 255:1377–1384PubMedGoogle Scholar
  74. Fromenty B, Lettéron P, Fisch C, Berson A, Deschamps D, Pessayre D (1993) Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondria. Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels and cell survival. Biochem Pharmacol 46:421–432PubMedCrossRefGoogle Scholar
  75. Fromenty B, Grimbert S, Mansouri A, Beaugrand M, Erlinger S, Rötig A, Pessayre D (1995) Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology 108:193–200PubMedCrossRefGoogle Scholar
  76. Fromenty B, Mansouri A, Bonnefont JP, Courtois F, Munnich A, Rabier D, Pessayre D (1996) Most cases of medium-chain acyl-CoA dehydrogenase deficiency escape detection in France. Hum Genet 97:367–368PubMedCrossRefGoogle Scholar
  77. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, Debatin KM (1998) Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 273:33942–33948PubMedCrossRefGoogle Scholar
  78. Genève J, Hayat-Bonan B, Labbe G, Degott C, Lettéron P, Fréneaux E, Le Dinh T, Larrey D, Pessayre D (1987a) Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 242:1133–1137PubMedGoogle Scholar
  79. Genève J, Larrey D, Amouyal G, Belghiti J, Pessayre D (1987b) Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450. Biochem Pharmacol 36:2421–2424PubMedCrossRefGoogle Scholar
  80. Ginsburg H, Geary TG (1987) Current concepts and new ideas on the mechanism of action of quinoline-containing antimalarials. Biochem Pharmacol 36:1567–1576PubMedCrossRefGoogle Scholar
  81. Grimbert S, Fromenty B, Fisch C, Lettéron P, Berson A, Durand-Schneider AM, Feldmann G, Pessayre D (1993) Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. Hepatology 17:628–637PubMedCrossRefGoogle Scholar
  82. Grimbert S, Fisch C, Deschamps D, Berson A, Fromenty B, Feldmann G, Pessayre D (1995) Effects of female sex hormones on liver mitochondria in non-pregnant female mice: possible role in acute fatty liver of pregnancy. Am J Physiol 268(Gastrointest Liver Physiol):G107–G115Google Scholar
  83. Grislain L, Gelé P, Bertrand M, Luijten W, Bromet N, Salvadori C, Kamoun A (1990) The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers. Drug Metab Dispos 18:804–808PubMedGoogle Scholar
  84. Grunnet N, Kondrup J (1986) The effect of ethanol on the ß-oxidation of fatty acids. Alcohol Clin Exp Res 10:64S–68SPubMedCrossRefGoogle Scholar
  85. Guigui B, Perrot S, Berry JP, Fleury-Feith J, Martin N, Métreau JM, Dhumeaux D, Zafrani ES (1988) Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 8:1063–1068PubMedCrossRefGoogle Scholar
  86. Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N (2006) c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131:165–178PubMedCrossRefGoogle Scholar
  87. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Cohen BH (2007) Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 120:1326–1333PubMedCrossRefGoogle Scholar
  88. Hägg M, Berndtsson M, Mandic A, Zhou R, Shoshan MC, Linder S (2004) Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. Mol Cancer Ther 3:489–497PubMedCrossRefGoogle Scholar
  89. Haouzi D, Lekehal M, Moreau A, Moulis G, Feldmann G, Robin MA, Lettéron P, Fau D, Pessayre D (2000) Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation and apoptosis in rat hepatocytes. Hepatology 32:303–311PubMedCrossRefGoogle Scholar
  90. Herraiz M, Beraza N, Solano A, Sangro B, Montoya J, Qian C, Prieto J, Bustos M (2003) Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther 14:463–472PubMedCrossRefGoogle Scholar
  91. Hostetler KY, Reasor M, Yazaki PJ (1985) Chloroquine-induced phospholipid fatty liver. Measurement of drug and lipid concentrations in rat liver lysosomes. J Biol Chem 260:215–219PubMedGoogle Scholar
  92. Hurwitz ES, Barrett MJ, Bregman D, Gunn WJ, Schonberger LB, Fairweather WR, Drage JS, LaMontagne JR, Kaslow RA, Burlington DB, Quinnan GV, Parker RA, Phillips K, Pinsky P, Dayton D, Dowdle WR (1985) Public health service study on Reye’s syndrome and medications. Report of the pilot phase. N Engl J Med 313:849–857PubMedCrossRefGoogle Scholar
  93. Ibdah JA, Bennet MJ, Rinaldo P, Zhao Y, Gibson B, Sims HF, Strauss AW (1999) A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. New Engl J Med 340:1723–1731PubMedCrossRefGoogle Scholar
  94. Inagaki H, Matsushima Y, Ohshima M, Kitagawa Y (1997) Interferons suppress mitochondrial gene transcription by depleting mitochondrial transcription factor A (mtTFA). J Interferon Cytokine Res 17:263–269PubMedGoogle Scholar
  95. Itoh S, Igarashi M, Tsukada Y, Ichinoe A (1977) Non-alcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepato-Gastroenterol 24:415–418Google Scholar
  96. Iwaasa M, Umeda S, Ohsato T, Takamatsu C, Fukuoh A, Iwasaki H, Shinagawa H, Hamasaki N, Kang D (2002) 1-Methyl-4-phenypyridinium, a toxin that can cause parkinsonism, alters branched structures of DNA. J Neurochem 82:30–37PubMedCrossRefGoogle Scholar
  97. Ji C, Mehrian-Shai R, Chan C, Hsu YH, Kaplowitz N (2005) Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcohol Clin Exp Res 29:1486–1503CrossRefGoogle Scholar
  98. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KE (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 276:40847–40857PubMedCrossRefGoogle Scholar
  99. Kågedal K, Johansson AC, Johansson U, Heimlich G, Roberg K, Wang NS, Jürgensmeier JM, Öllinger K (2005) Lysosomal membrane permeabilization during apoptosis - involvement of Bax? Intl J Exp Pathol 86:309–321CrossRefGoogle Scholar
  100. Kamal MA, French SW (2004) Drug-induced mitochondrial biogenesis in a liver biopsy. Exp Mol Pathol 77:201–204PubMedCrossRefGoogle Scholar
  101. Kaplan MM (1985) Acute fatty liver of pregnancy. N Engl J Med 313:367–370PubMedCrossRefGoogle Scholar
  102. Karbowski M, Kurono C, Wozniak M, Ostrowski M, Teranishi M, Nishizawa Y, Usukura J, Soji T, Wakabayashi T (1999) Free radical-induced megamitochondria formation and apoptosis. Free Radic Biol Med 26:396–409PubMedCrossRefGoogle Scholar
  103. Kassahun K, Farrell K, Abbott F (1991) Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos 19:525–535PubMedGoogle Scholar
  104. Kassahun K, Hu P, Grillo MP, Davis MR, Jin L, Baillie TA (1994) Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent mechanisms. Chem Biol Interact 90:253–275PubMedCrossRefGoogle Scholar
  105. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, Baillie TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62–70PubMedCrossRefGoogle Scholar
  106. Katewa SD, Katyare SS (2004) Treatment with antimalarials adversely affects the oxidative energy metabolism in rat liver mitochondria. Drug Chem Toxicol 27:41–53PubMedCrossRefGoogle Scholar
  107. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krähenbühl S (2005) Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41:925–935PubMedCrossRefGoogle Scholar
  108. Kelly DP, Whelan AJ, Ogden ML, Alpers R, Zhang Z, Bellus G, Gregersen N, Dorland L, Strauss AW (1990) Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci USA 87:9236–9240PubMedCrossRefGoogle Scholar
  109. Killenberg PG, Davidson ED, Webster LT (1971) Evidence for a medium-chain fatty acid coenzyme A ligase (adenosine monophosphate) that activates salicylate. Mol Pharmacol 7:260–268PubMedGoogle Scholar
  110. Kodavanti UP, Mehendale HM (1990) Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 42:327–354PubMedGoogle Scholar
  111. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280:37481–37488PubMedCrossRefGoogle Scholar
  112. Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lücking CH (2001) Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 11:757–759PubMedCrossRefGoogle Scholar
  113. Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straussmann D (2000) Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20:346–348PubMedCrossRefGoogle Scholar
  114. Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6:513–519PubMedCrossRefGoogle Scholar
  115. Kroon AM, de Vries H (1969) The effects of chloramphenicol on the biogenesis of mitochondria of rat liver in vivo. FEBS Lett 3:208–210PubMedCrossRefGoogle Scholar
  116. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, Ohtsuka E, Nishimura S (1987) Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and adjacent residues. Nature 327:77–79PubMedCrossRefGoogle Scholar
  117. Kukielka E, Cederbaum AI (1989) NADH-dependent microsomal interaction with ferric complexes and production of reactive oxygen species. Arch Biochem Biophys 275:540–550PubMedCrossRefGoogle Scholar
  118. Kukielka E, Dicker E, Cederbaum AI (1994) Increased production of reactive oxygen species by rat liver mitochondria after chronic ethanol treatment. Arch Biochem Biophys 309:377–386PubMedCrossRefGoogle Scholar
  119. Labbe G, Fromenty B, Fréneaux E, Morzelle V, Lettéron P, Berson A, Pessayre D (1991) Effects of various tetracycline derivatives on in vitro and in vivo β-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. Biochem Pharmacol 41:638–641PubMedCrossRefGoogle Scholar
  120. Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and prediction during preclinical studies. Fund Clin Pharmacol 22:335CrossRefGoogle Scholar
  121. Lam CW, Lau CH, Williams JC, Cahn YW, Wong LJC (1997) Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 156:562–564PubMedCrossRefGoogle Scholar
  122. Larosche I, Letteron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, Mansouri A (2007) Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 321:526–535PubMedCrossRefGoogle Scholar
  123. Larrey D, Castot A, Pessayre D, Mérigot P, Machayekhy JP, Feldmann G, Lenoir A, Rueff B, Benhamou JP (1986) Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 104:801–803PubMedGoogle Scholar
  124. Larrey D, Tinel M, Lettéron P, Maurel P, Loeper J, Belghiti J, Pessayre D (1990) Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P-450. Biochem Pharmacol 40:545–550PubMedCrossRefGoogle Scholar
  125. Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC (1993) 4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 Leukemia cells. J Cell Biochem 51:165–174PubMedCrossRefGoogle Scholar
  126. Lawrence JW, Claire DC, Weissig V, Rowe TC (1996) Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 50:1178–1188PubMedGoogle Scholar
  127. Lazarczyk DA, Gordon SC, Goldstein NS (2001) Trovafloxacin hepatotoxicity. Dig Dis Sci 46:925–926PubMedCrossRefGoogle Scholar
  128. Le Dinh T, Fréneaux E, Labbe G, Lettéron P, Degott C, Genève J, Berson A, Larrey D, Pessayre D (1988) Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 247:745–750PubMedGoogle Scholar
  129. Le Roy F, Bisbal C, Silhol M, Martinand C, Lebleu B, Salehzada T (2001) The 2–5A/RNase L/RNase inhibitor (RLI) pathway regulates mitochondrial mRNAs stability in interferon-α-treated H9 cells. J Biol Chem 276:48473–48482PubMedCrossRefGoogle Scholar
  130. Le Roy F, Silhol M, Salehzada T, Bisbal C (2007) Regulation of mitochondrial mRNA stability by RNase L is translation-dependent and controls IFNalpha-induced apoptosis. Cell Death Differ 14:1406–1413PubMedCrossRefGoogle Scholar
  131. LeDoux SP, Driggers WJ, Hollensworth BS, Wilson GL (1999) Repair of alkylation and oxidative damage in mitochondrial DNA. Mutation Res 434:149–159PubMedCrossRefGoogle Scholar
  132. Leist M, Single B, Castoldi AF, Kühnle S, Nicotera P (1997) Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185:1481–1486PubMedCrossRefGoogle Scholar
  133. Lettéron P, Duchatelle V, Berson A, Fromenty B, Fisch C, Degott C, Benhamou JP, Pessayre D (1993) Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol abusers. Gut 34:409–414PubMedCrossRefGoogle Scholar
  134. Lettéron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D (1997) Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid β-oxidation. Am J Physiol 272(Gastrointest Liver Physiol 35):G1141–G1150Google Scholar
  135. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D (2003) Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38:133–140PubMedCrossRefGoogle Scholar
  136. Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, Acheampong A, Tor J, Guyot M, Loiseau P (1990) Effects of polytherapy with phenytoin, carbamazepine and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 48:225–235PubMedCrossRefGoogle Scholar
  137. Lewis W, Dalakas MC (1995) Mitochondrial toxicity of antiviral drugs. Nature Med 1:417–422PubMedCrossRefGoogle Scholar
  138. Lewis JA, Huq A, Najarro P (1996a) Inhibition of mitochondrial function by interferon. J Biol Chem 22:13184–13190Google Scholar
  139. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, Watanabe KA, Perrino FW (1996b) Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 93:3592–3597PubMedCrossRefGoogle Scholar
  140. Lewis W, Copeland WC, Day BJ (2001) Mitochondrial DNA depletion, oxidative stress and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 81:777–790PubMedCrossRefGoogle Scholar
  141. Li TK, Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41:53–77PubMedCrossRefGoogle Scholar
  142. Liguori MJ, Anderson MG, Bukofzer S, McKim J, Pregenzer JF, Retief J, Spear BB, Waring JF (2005) Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41:177–186PubMedCrossRefGoogle Scholar
  143. Lin JH, Castora FJ (1991) DNA topoisomerase II from mammalian mitochondria is inhibited by the antitumor drugs, m-ASA and VM-26. Biochem Biophys Res Commun 176:690–697PubMedCrossRefGoogle Scholar
  144. Lin MCM, Li JJ, Wang EJ, Princler GL, Kauffman FC, Kung HF (1997) Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. FASEB J 11:1145–1152PubMedGoogle Scholar
  145. Linnett PE, Mitchell AD, Osselton MD, Muhleirn LJ, Beechey RB (1978) Citreoviridin, a specific inhibitor of the mitochondrial adenosine triphosphatase. Biochem J 170:503–510PubMedGoogle Scholar
  146. Loeper J, Descatoire V, Lettéron P, Moulis C, Degott C, Dansette P, Fau D, Pessayre D (1994) Hepatotoxicity of germander in mice. Gastroenterology 106:464–472PubMedGoogle Scholar
  147. Lynx MD, McKee EE (2006) 3′-Azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 72:239–243PubMedCrossRefGoogle Scholar
  148. Maggs JL, Kitteringham NR, Breckenridge AM, Park BK (1987) Autoxidative formation of a chemically reactive intermediate from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem Pharmacol 36:2061–2062PubMedCrossRefGoogle Scholar
  149. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Kärppä M, Majamaa-Voltti KAM, Rusanen H, Sorri M, Peuhkurienen KJ, Hassinen IE (1998) Epidemiology of the A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Human Genet 63:447–454CrossRefGoogle Scholar
  150. Mallon PWG, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, Cooper DA, Carr A, and the SAMA investigators (2005) In vivo, nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 191:1686–1696Google Scholar
  151. Mandel H, Hartman C, Berkowitz D, Elpeleg ON, Manov I, Iancu TC (2001) The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. Hepatology 34:776–784PubMedCrossRefGoogle Scholar
  152. Mansouri A, Fromenty B, Berson A, Robin MA, Grimbert S, Beaugrand M, Erlinger S, Pessayre D (1997) Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients. J Hepatol 27:96–102PubMedCrossRefGoogle Scholar
  153. Mansouri A, Gaou I, De Kerguenec C, Amsellem S, Haouzi D, Berson A, Moreau A, Feldmann G, Lettéron P, Pessayre D, Fromenty B (1999) An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 117:181–190PubMedCrossRefGoogle Scholar
  154. Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B (2001) Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart and skeletal muscles. Protective effects of antioxidants. J Pharmacol Exp Ther 298:737–743PubMedGoogle Scholar
  155. Mansouri A, Haouzi D, Descatoire V, Demieilliers C, Sutton A, Vadrot N, Fromenty B, Feldmann G, Pessayre D, Berson A (2003) Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology 38:715–725PubMedCrossRefGoogle Scholar
  156. Maria VA, Pinto L, Victorino RM (1994) Lymphocyte reactivity to ex-vivo drug antigens in drug-induced hepatitis. J Hepatol 21:151–158PubMedCrossRefGoogle Scholar
  157. Martin AM, Hammond E, Nolan D, Pace C, Boer MD, Taylor L, Moore H, Martinez OP, Christiansen FT, Mallal S (2003) Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse transcriptase inhibitors. Am J Hum Genet 72:549–560PubMedCrossRefGoogle Scholar
  158. Masubuchi Y, Nakayama S, Horie T (2002) Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35:544–551PubMedCrossRefGoogle Scholar
  159. Masubuchi Y, Suda C, Horie T (2005) Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 42:110–116PubMedCrossRefGoogle Scholar
  160. Matsuno-Yagi A, Hatefi Y (1993) Studies on the mechanism of oxidative phosphorylation. Different effects of F0 inhibitors on unisite and multisite ATP hydrolysis by bovine submitochondrial particles. J Biol Chem 268:1539–1545PubMedGoogle Scholar
  161. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Biseglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New Engl J Med 333:1099–1105PubMedCrossRefGoogle Scholar
  162. Melegh B, Pap M, Molnár D, Masszi G, Kopcsányi G (1997) Carnitine administration ameliorates the changes in energy metabolism caused by short-term pivampicillin medication. Eur J Pediatr 156:795–799PubMedCrossRefGoogle Scholar
  163. Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G (1999) Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 286:774–779PubMedCrossRefGoogle Scholar
  164. Miller ME, Brooks JG, Forbes N, Insel R (1992) Frequency of medium-chain acyl-CoA dehydrogenase deficiency G-985 mutation in sudden infant death syndrome. Pediatr Res 31: 305–307PubMedCrossRefGoogle Scholar
  165. Mitsuya H, Broder S (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 83:1911–1915PubMedCrossRefGoogle Scholar
  166. Miyako K, Kai Y, Irie T, Takeshige K, Kang D (1997) The content of intracellular mitochondrial DNA is decreased by 1-methyl-4-phenylpyridium ion (MPP+). J Biol Chem 272: 9605–9608PubMedCrossRefGoogle Scholar
  167. Montenez JP, Van Bambeke F, Piret J, Brasseur R, Tulkens PM, Mingeot-Leclercq MP (1999) Interactions of macrolide antibiotics (erythromycin A, roxithromycin, erythromycylamine [Dirithromycin] and azithromycin) with phospholipids: computer-aided conformation analysis and studies on acellular and cell culture models. Toxicol Appl Pharmacol 156:129–140PubMedCrossRefGoogle Scholar
  168. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S (1984) Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 10:1057–1064CrossRefGoogle Scholar
  169. Morris AAM (1999) Mitochondrial respiratory chain disorders and the liver. Liver 19:357–368PubMedCrossRefGoogle Scholar
  170. Morris AAM, Taanman JW, Blake J, Cooper JM, Lake BD, Malone M, Love S, Clayton PT, Leonard JV, Schapira AHV (1998) Liver failure associated with mitochondrial DNA depletion. J Hepatol 28:556–563PubMedCrossRefGoogle Scholar
  171. Mourier T, Hansen AJ, Willerslev E, Arctander P (2001) The human genome projects reveal a continuous transfer of large mitochondrial fragments to the nucleus. Mol Biol Evol 18:1833–1837PubMedCrossRefGoogle Scholar
  172. Nass MM (1984) Analysis of methylglyoxal bis(guanylhydrazone)-induced alterations of hamster tumor mitochondria by correlated studies of selective rhodamine binding, ultrastructural damage, DNA replication and reversibility. Cancer Res 44:2677–2688PubMedGoogle Scholar
  173. Nechushtan A, Smith CL, Lamensdorf I, Yoon SH, Youle RJ (2001) Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 153:1265–1276PubMedCrossRefGoogle Scholar
  174. Njoku DB, Greenberg RS, Bourdi M, Borkowf CB, Dake EM, Martin JL, Pohl LR (2002) Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 94:243–249PubMedGoogle Scholar
  175. Njølstad PR, Skjeldal OH, Agsteribbe E, Huckriede A, Wannag E, Søvik O, Waaler PE (1997) Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity. Pediatr Neurol 16:160–162PubMedCrossRefGoogle Scholar
  176. Noda S, Umezaki H, Yamamoto K, Araki T, Murakami T, Ishii N (1988) Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate. J Neurol Neurosurg Psychiatry 51:582–585PubMedCrossRefGoogle Scholar
  177. Nordmann R, Ribière C, Rouach H (1992) Implication of free radical mechanisms in ethanol-induced cellular injury. Free Radical Biol Med 112:219–240CrossRefGoogle Scholar
  178. Oh KW, Qian T, Brenner DA, Lemasters JJ (2003) Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol Sci 73:44–52PubMedCrossRefGoogle Scholar
  179. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K (1996) Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25:283–291PubMedCrossRefGoogle Scholar
  180. Oleinick NL, Corcoran JW (1969) Two types of binding of erythromycin to ribosomes from antibiotic-sensitive and resistant Bacillus subtilis 168. J Biol Chem 244:727–735PubMedGoogle Scholar
  181. Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Diff 11:381–389CrossRefGoogle Scholar
  182. Paquet C, Sané AT, Beauchemin M, Bertrand R (2005) Caspase- and mitochondrial dysfunction-dependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis. Leukemia 19:784–791PubMedCrossRefGoogle Scholar
  183. Partin JS, Daugherty CC, McAdams AJ, Partin JC, Schubert WK (1984) A comparison of liver ultrastructure in salicylate intoxication and Reye’s syndrome. Hepatology 4:687–690PubMedCrossRefGoogle Scholar
  184. Pastorino JG, Simbula G, Yamamoto K, Glascott PA Jr, Rothman RJ, Farber JL (1996) The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition. J Biol Chem 271:29792–29798PubMedCrossRefGoogle Scholar
  185. Pérez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA (2003) Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38:999–1007PubMedGoogle Scholar
  186. Pessayre D (1995) Role of reactive metabolites in drug-induced hepatitis. J Hepatol 23:S16–S24Google Scholar
  187. Pessayre D (2007) Mitochondria and energy formation. In: Rodes J, Benhamou JP, Blei AT, Reichen J, Rizzetto M (eds) Textbook of hepatology: from basic science to clinical practice, 3rd edn. Blackwell Publishing, Oxford, pp 149–165Google Scholar
  188. Pessayre D, Fromenty B (2005) NASH: a mitochondrial disease. J Hepatol 42:928–940PubMedCrossRefGoogle Scholar
  189. Pessayre D, Larrey D (2007) Drug-induced liver injury. In: Rodes J, Benhamou JP, Blei AT, Reichen J, Rizzetto M (eds) Textbook of hepatology: from basic science to clinical practice, 3rd edn. Blackwell Publishing, Oxford, pp 1211–1268Google Scholar
  190. Pessayre D, Bichara M, Feldmann G, Degott C, Potet F, Benhamou JP (1979) Perhexiline maleate-induced cirrhosis. Gastroenterology 76:170–177PubMedGoogle Scholar
  191. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP (1985) Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 16(suppl A):181–194Google Scholar
  192. Pessayre D, Haouzi D, Fau D, Robin MA, Mansouri A, Berson A (1999) Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. J Hepatol 31:760–770PubMedCrossRefGoogle Scholar
  193. Pessayre D, Feldmann G, Haouzi D, Fau D, Moreau A, Neuman M (2000) Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous substances and foreign toxins). In: Cameron RG, Feuer G (eds) Apoptosis and its modulation by drugs. Springer, Heidelberg. Handbook Exp Pharmacol 142:59–108Google Scholar
  194. Pessayre D, Fromenty B, Mansouri A (2001) Drug-induced steatosis and steatohepatitis. In: Lemasters JJ, Niemenen AL (eds) Mitochondria in pathogenesis. Kluwer Academic/Plenum Publishers, New York, pp 489–517Google Scholar
  195. Pessayre D, Fromenty B, Mansouri A, Berson A (2007) Hepatotoxicity due to mitochondrial dysfunction. In: Kaplowitz N, DeLeve LD (eds) Drug-induced liver disease, 3rd edn. Informa Healthcare USA, New York, pp 49–84Google Scholar
  196. Pessayre D, Berson A, Fromenty B (2008) Features and mechanisms of drug-induced liver injury. In: Dykens J, Will Y (eds) Mitochondrial Dysfunction. John Willey and Sons, Hoboken, pp (in press)Google Scholar
  197. Piccoli C, Scrima R, Quarato G, D'Aprile A, Ripoli M, Lecce L, Boffoli D, Moradpour D, Capitanio N (2007) Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 46:58–65PubMedCrossRefGoogle Scholar
  198. Pinz KG, Shibutani S, Bogenhagen DF (1995) Action of mitochondrial DNA polymerase γ at sites of base loss or oxidative damage. J Biol Chem 270:9202–9206PubMedCrossRefGoogle Scholar
  199. Polavarapu R, Spitz DR, Sim JE, Follansbee MH, Oberley LW, Rahemtulla A, Nanji AA (1988) Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology 27:1317–1323CrossRefGoogle Scholar
  200. Ponchaut S, Van Hoof F, Veitch K (1992) In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 43:2435–2442PubMedCrossRefGoogle Scholar
  201. Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, Blendis L, Phillips MJ (1984) Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 86:926–936PubMedGoogle Scholar
  202. Qian T, Herman B, Lemasters J (1999) The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol Appl Pharmacol 154:117–125PubMedCrossRefGoogle Scholar
  203. Rahmani Z, Huh KW, Lasher R, Siddiqui A (2002) Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J Virol 74:2840–2846CrossRefGoogle Scholar
  204. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsh F, Goulbern M, Poupon MF, Miccoli L, Xie Z, Reed JC, Kroemer G (1999) Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18:2537–2546PubMedCrossRefGoogle Scholar
  205. Reid AB, Kurten RC, McCullough SS, Brock RW, Hinson JA (2005) Mechanisms of acetaminophen-induced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J Pharmacol Exp Ther 312:509–516PubMedCrossRefGoogle Scholar
  206. Remington PL, Rowley D, McGee H, Hall WN, Monto AS (1986) Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984. Pediatrics 77:93–98PubMedGoogle Scholar
  207. Ress BD, Gross EM (2000) Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. Ann Otol Rhinol Laryngol 109:435–437PubMedGoogle Scholar
  208. Robin MA, Maratrat M, Le Roy M, Le Breton FP, Bonnerbiale E, Dansette P, Ballet F, Mansuy D, Pessayre D (1996) Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest 98:1471–1480PubMedCrossRefGoogle Scholar
  209. Robin MA, Le Roy M, Descatoire V, Pessayre D (1997) Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 26(suppl 1):23–30Google Scholar
  210. Robin MA, Sauvage I, Grandperret T, Descatoire V, Pessayre D, Fromenty B (2005) Ethanol increases mitochondrial cytochrome P450 2E1 in mouse liver and rat hepatocytes. FEBS Lett 579:6895–6902PubMedCrossRefGoogle Scholar
  211. Robin MA, Albano V, Pessayre D, Berson A (2008) Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory–Denk body formation. Toxicol In Vitro 22:1511–1519Google Scholar
  212. Rowe PC, Valle D, Brusilow SW (1988) Inborn errors of metabolism in children referred with Reye’s syndrome: a changing pattern. JAMA 260:3167–3170PubMedCrossRefGoogle Scholar
  213. Rowe TC, Weissig V, Lawrence JW (2001) Mitochondrial DNA metabolism targeting drugs. Adv Drug Deliv Rev 49:175–187PubMedCrossRefGoogle Scholar
  214. Sadeque AJM, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283:698–703PubMedGoogle Scholar
  215. Salomon AR, Voehringer DW, Herzenberg LA, Khosla C (2001) Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem Biol 8:71–80PubMedCrossRefGoogle Scholar
  216. Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14:778–809PubMedCrossRefGoogle Scholar
  217. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183–1192PubMedCrossRefGoogle Scholar
  218. Saudubray JM, Martin D, de Lonlay P, Touati G, Poggi-Travert F, Bonnet D, Jouvet P, Boutron G, Slama A, Vianey-Saban C, Bonnefont JP, Rabier D, Kamoun P, Brivet M (1999) Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inher Metab Dis 22:488–502PubMedCrossRefGoogle Scholar
  219. Sbarra C, Castelli MG, Noseda A, Fanelli R (1981) Pharmacokinetics of amineptine in man. Eur J Drug Metab Pharmacokinet 6:123–126Google Scholar
  220. Schneider Berlin KR, Ammini CV, Rowe TC (1998) Dequalinium induces a selective depletion of mitochondrial DNA from HeLa human cervical carcinoma cells. Exp Cell Res 245:137–145PubMedCrossRefGoogle Scholar
  221. Schneider E, Hsiang YH, Liu LF (1990) DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149–183PubMedCrossRefGoogle Scholar
  222. Schon EA, Bonilla E, DiMauro S (1997) Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr 29:131–149PubMedCrossRefGoogle Scholar
  223. Seef LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB (1986) Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 104:399–404Google Scholar
  224. Sepuri NB, Yadav S, Anandatheerthavarada HK, Avadhani NG (2007) Mitochondrial targeting of intact CYP2B1 and CYP2E1 and N-terminal truncated CYP1A1 proteins in Saccharomyces cerevisiae–role of protein kinase A in the mitochondrial targeting of CYP2E1. FEBS J 274:4615–4630PubMedCrossRefGoogle Scholar
  225. Setzer B, Lebrecht D, Walker UA (2008) Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 172:681–690PubMedCrossRefGoogle Scholar
  226. Shan B, Vazquez E, Lewis JA (1990) Interferon selectively inhibits the expression of mitochondrial genes: a novel pathway for interferon-mediated responses. EMBO J 9:4307–4314PubMedGoogle Scholar
  227. Shekhawat P, Bennett MJ, Sadovsky Y, Nelson DM, Rakheja D, Strauss AW (2003) Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am J Physiol Endocrinol Metab 284:E1098–E1105PubMedGoogle Scholar
  228. Shigenaga MK, Hagen TM, Ames BN (1999) Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 91:10771–10778CrossRefGoogle Scholar
  229. Shishido S, Koga H, Harada M, Kumemura H, Hanada S, Taniguchi E, Kumashiro R, Ohira H, Sato Y, Namba M, Ueno T, Sata M (2003) Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37:136–147PubMedCrossRefGoogle Scholar
  230. Silva MFB, Ruiter JPN, Ijlst L, Jakobs C, Duran M, de Almeida IT, Wanders RJA (1997) Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation. J Inher Metab Dis 20:397–400PubMedCrossRefGoogle Scholar
  231. Song S, Wheeler LJ, Mathews CK (2003) Deoxyribonucleotide pool imbalance stimulates deletions in HeLa cell mitochondrial DNA. J Biol Chem 278:43893–43896PubMedCrossRefGoogle Scholar
  232. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35:182–189PubMedCrossRefGoogle Scholar
  233. Sun Q, Zhu R, Foss FW Jr, Macdonald TL (2008) In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity. Chem Res Toxicol 2:711–719CrossRefGoogle Scholar
  234. Susin SA, Zamzami N, Kroemer G (1998) Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366:151–165PubMedCrossRefGoogle Scholar
  235. Szczesny B, Hazra TK, Papaconstantinou J, Mitra S, Boldogh I (2003) Age-dependent deficiency in import of mitochondrial DNA glycosylases required for repair of oxidatively damaged bases. Proc Natl Acad Sci USA 100:10670–10675PubMedCrossRefGoogle Scholar
  236. Taanman JW (1999) The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta 1410:103–123PubMedCrossRefGoogle Scholar
  237. Terrinoni A, Ranalli M, Cadot B, Leta A, Bagetta G, Vousden KH, Melino G (2004) p73-alpha is capable of inducing scotin and ER stress. Oncogene 23:3721–3725PubMedCrossRefGoogle Scholar
  238. Thust R, Tomicic M, Klöcking R, Voutilainen N, Wutzler P, Kaina B (2000) Comparison of the genotoxic and apoptosis–inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches. Cancer Gene Ther 7:107–117PubMedCrossRefGoogle Scholar
  239. Trost LC, Lemasters JJ (1996) The mitochondrial permeability transition: a new pathophysiological mechanism for Reye’s syndrome and toxic liver injury. J Pharmacol Exp Ther 278:1000–1005PubMedGoogle Scholar
  240. Tsuchishima M, Tsutsumi M, Shiroeda H, Yano H, Ueshima Y, Shimanaka K, Takase S (2000) Study of mitochondrial DNA deletion in alcoholics. Alcohol Clin Exp Res 24:12S–15SPubMedGoogle Scholar
  241. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang H-J, Takenaka H, Tsuchiya T, Mori M, Mizushima T (2004) Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Diff 11:1009–1016CrossRefGoogle Scholar
  242. Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HAS (1983) The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. Biochem Pharmacol 32:1887–1892PubMedCrossRefGoogle Scholar
  243. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG (2001) Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34:101–108PubMedCrossRefGoogle Scholar
  244. Ulrich RG, Bacon JA, Brass EP, Cramer CT, Petrella DK, Sun EL (2001) Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem Biol Interact 134:251–270PubMedCrossRefGoogle Scholar
  245. Urano F, Wang XZ, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D (2000) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane kinase IRE1. Science 287:664–666PubMedCrossRefGoogle Scholar
  246. van der Klauw MM, Houtman PM, Stricker BH, Spoelstra P (1994) Hepatic injury caused by benzbromarone. J Hepatol 20:376–379PubMedCrossRefGoogle Scholar
  247. Vásquez-Vivar J, Augusto O (1992) Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J Biol Chem 267:6848–6854PubMedGoogle Scholar
  248. Victorino RM, Silveira JC, Baptista A, de Moura MC (1980) Jaundice associated with naproxen. Postgrad Med J 56:368–370PubMedCrossRefGoogle Scholar
  249. Walker UA, Venhoff N (2005) Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 10(Suppl 2):M117–M123PubMedGoogle Scholar
  250. Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J (2004) Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine or zalcitabine. Hepatology 39:311–317PubMedCrossRefGoogle Scholar
  251. Wallace DC (1999) Mitochondrial disease in man and mouse. Science 283:1482–1488PubMedCrossRefGoogle Scholar
  252. Watkins PB, Zimmermann HJ, Knapp MJ, Gracon SI, Lewis KW (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 271:992–998PubMedCrossRefGoogle Scholar
  253. Watmough NJ, Bindoff LA, Birch-Machin MA, Jackson S, Bartlett K, Ragan CI, Poulton J, Gardiner RM, Sherratt HSA, Turnbull DM (1990) Impaired mitochondrial ß-oxidation in a patient with an abnormality of the respiratory chain. Studies in skeletal muscle mitochondria. J Clin Invest 85:177–184PubMedCrossRefGoogle Scholar
  254. Weis M, Kass GE, Orrenius S, Moldéus P (1992) N-acetyl-p-benzoquinone imine induces Ca2+ release from mitochondria by stimulating pyridine nucleotide hydrolysis. J Biol Chem 267:804–809PubMedGoogle Scholar
  255. Weiss CF, Glazko AJ, Weston JK (1960) Chloramphenicol in the newborn infant. A physiologic explanation for its toxicity when given in excessive doses. N Engl J Med 262:787–794PubMedCrossRefGoogle Scholar
  256. Wieckowski MR, Wojtczak L (1997) Involvement of the dicarboxylate carrier in the protonophoric action of long-chain fatty acids in mitochondria. Biochem Biophys Res Commun 232:414–417PubMedCrossRefGoogle Scholar
  257. Wieland P, Lauterburg BH (1995) Oxidation of mitochondrial proteins and DNA following administration of ethanol. Biochem Biophys Res Commun 213:815–819PubMedCrossRefGoogle Scholar
  258. Wiseman A, Attardi G (1978) Reversible tenfold reduction in mitochondria DNA content of human cells treated with ethidium bromide. Mol Gen Genet 167:51–63PubMedGoogle Scholar
  259. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM (2002) Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 186:23–31PubMedCrossRefGoogle Scholar
  260. Yang D, Oyaizu Y, Oyaizu H, Olsen GJ, Woese CR (1985) Mitochondrial origins. Proc Natl Acad Sci USA 82:4443–4447PubMedCrossRefGoogle Scholar
  261. Yarchoan R, Mitsuya H, Myers CE, Broder S (1989) Clinical pharmacology of 3′-azido-2′, 3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 321:726–738PubMedCrossRefGoogle Scholar
  262. Yokota I, Saijo T, Vockley J, Tanaka K (1992) Impaired tetramer assembly of variant medium-chain acyl-coenzyme A dehydrogenase with a glutamate or aspartate substitution for lysine 304 causing instability of the protein. J Biol Chem 267:26004–26010PubMedGoogle Scholar
  263. You M, Fischer M, Deeg MA, Crabb DW (2002) Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 277:29342–29347PubMedCrossRefGoogle Scholar
  264. Yunis AA (1989) Chloramphenicol toxicity: 25 years of research. Am J Med 87:44N–48NPubMedGoogle Scholar
  265. Zhang Z, Kolvraa S, Zhou Y, Kelly DP, Gregersen N, Strauss AW (1993) Three RFLPs defining a haplotype associated with the common mutation in human medium-chain acyl-CoA dehydrogenase (MCAD) deficiency occur in Alu repeats. Am J Hum Genet 52:1111–1121PubMedGoogle Scholar
  266. Zhang Y, Bell A, Perlman PS, Leibowitz MJ (2000) Pentamidine inhibits mitochondrial intron splicing and translation in Saccharomyces cerevisiae. RNA 6:937–951PubMedCrossRefGoogle Scholar
  267. Zhang H, Barceló JM, Lee B, Kohlhagen G, Zimonjic DB, Popescu NC, Pommier Y (2001) Human mitochondrial topoisomerase I. Proc Natl Acad Sci USA 98:10608–10613PubMedCrossRefGoogle Scholar
  268. Zhao H, Cai Y, Santi S, Lafrenie R, Lee H (2005) Chloroquine-mediated radiosensitization is due to the destabilisation of the lysosomal membrane and subsequent induction of cell death by necrosis. Radiat Res 164:250–257PubMedCrossRefGoogle Scholar
  269. Zheng J, Ramirez VD (1999) Rapid inhibition of rat brain mitochondrial proton F0F1-ATPase activity by estrogens: comparison with Na + , K + -ATPase of porcine cortex. Eur J Pharmacol 368:95–102PubMedCrossRefGoogle Scholar
  270. Zheng J, Ramirez VD (2000) Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 130:1115–1123PubMedCrossRefGoogle Scholar
  271. Zhou H, Gurley EC, Jarujaron S, Ding H, Fang Y, Xu Z, Pandak WM, Hylemon PB (2006) HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am J Physiol Gastrointest Liver Physiol 291:1071–1080CrossRefGoogle Scholar
  272. Zimmerman HJ (1978) Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. Appleton-Century-Crofts, New YorkGoogle Scholar
  273. Zimmerman HJ (1981) Effects of aspirin and acetaminophen on the liver. Arch Intern Med 141:333–342PubMedCrossRefGoogle Scholar
  274. Zimmerman HJ, Ishak KG (1982) Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2:591–597PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Dominique Pessayre
    • 1
    Email author
  • Abdellah Mansouri
  • Alain Berson
  • Bernard Fromenty
  1. 1.INSERM U773Faculté de Médecine Xavier BichatParisFrance

Personalised recommendations